Efficacy and safety of low-dose thrombolysis in intermediate-risk pulmonary embolism: a meta-analysis
Frontiers in Cardiovascular Medicine · 13.08.2026 · 13
DOI: 10.3389/fcvm.2026.1862385 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 13.08.2026. Verfasst von Chen Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzho…. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To systematically evaluate the efficacy and safety of low-dose thrombolysis in patients with intermediate-risk pulmonary embolism (PE).
Methods
A systematic search was conducted in PubMed, Embase, and the Cochrane Library up to December 6, 2025. Randomized controlled trials (RCTs), non-randomized controlled studies, and cohort studies investigating low-dose thrombolysis for intermediate-risk PE were included. Two researchers independently screened the literature, extracted data, and assessed study quality. A meta-analysis was performed using Stata software (version 16.0) to calculate pooled estimates of mortality, bleeding incidence, and recurrence rates. The efficacy and safety of low-dose thrombolysis were compared with those of anticoagulation alone or full-dose thrombolysis.
Results
This meta-analysis included 13 studies (1,018 patients with intermediate-risk PE). Low-dose thrombolysis yielded a 1-month and 1-year mortality of 2% (95% CI: 0.00–0.03; 0.00–0.05), recurrence of 1% (95% CI: 0.00–0.02), major bleeding of 1% (95% CI: 0.00–0.03), and minor bleeding of 7% (95% CI: 0.05–0.10). Subgroup analysis showed ultrasound-assisted catheter-directed thrombolysis (USAT) had 1-month and 1-year mortality rates of 2% (95% CI: 0.01–0.04) and 1% (95% CI: 0.00–0.03), respectively, vs. 1% (95% CI: 0.00–0.03) and 7% (95% CI: 0.01–0.16) for low-dose systemic thrombolysis. Compared to anticoagulation alone or full-dose thrombolysis, low-dose systemic thrombolysis showed no significant differences in mortality or recurrence, but had lower bleeding risk than full-dose thrombolysis (RD = −0.23, 95% CI: −0.44 to −0.01). USAT significantly reduced 1-month mortality vs. anticoagulation alone (RD = −0.09, 95% CI: −0.13 to −0.04); however, this stems from a single non-randomized study requiring RCT validation. Bleeding rates showed no significant difference.
Conclusion
In patients with intermediate-risk PE, low-dose thrombolysis yields low mortality and recurrence rates with an acceptable bleeding risk. Compared with full-dose thrombolysis, it offers a safety advantage by reducing the incidence of bleeding; however, its comparative efficacy regarding mortality and recurrence remains undetermined and may be equivalent. Further high-quality RCTs are warranted. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261284475 .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Intensive Care Unit, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Zitieren
APA
Zhu, C., Chen, W., Wang, L., & Xing, X. (2026). Efficacy and safety of low-dose thrombolysis in intermediate-risk pulmonary embolism: a meta-analysis. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1862385
Vancouver
Zhu C, Chen W, Wang L, Xing X. Efficacy and safety of low-dose thrombolysis in intermediate-risk pulmonary embolism: a meta-analysis. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1862385
BibTeX
@article{Zhu2026,
author = {Zhu, Chen and Chen, Wei and Wang, Lingcong and Xing, Xi},
title = {Efficacy and safety of low-dose thrombolysis in intermediate-risk pulmonary embolism: a meta-analysis},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1862385}
}
EUVIMED